Milano, Italy, October 2024 – CIS BIOPHARMA, a leading biopharmaceutical innovator participated in the 35th anniversary of CPHI in Milano, a premier international pharmaceutical event. This engagement underscores the company’s commitment to staying at the forefront of industry advancements and fostering key partnerships.
The event, which saw unprecedented participation with nearly 60,000 attendees from 108 countries and approximately 3,000 exhibiting companies, provided a comprehensive platform for networking and exploring cutting-edge industry trends.
Christoph Schäfer, the company’s CEO highlighted key focus areas of the conference: «CPHI Milano offered valuable insights into the topics shaping our industry’s future. Particularly noteworthy were the discussions on Manufacturing 5.0, the evolution of pharma and ingredients, the integration of AI and Large Language Models in biopharmaceutical research, and advancements in next-generation mRNA vaccines.»
He further emphasizes the event’s strategic value: «The conference provided an excellent opportunity to reconnect with key business partners and forge new relationships. Milano’s vibrant setting offered an ideal backdrop for celebrating our accomplishments and solidifying new agreements.»
About CIS BIOPHARMA AG
CIS BIOPHARMA is a privately-owned, Basel-based oncology company developing next-generation immuno-conjugates to address aggressive forms of tumors. The company’s product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, that selectively target tumor cells. CIS BIOPHARMA is committed to helping cancer patients live longer and better lives.